Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in glioblastoma and could support an accelerated pathway to US regulatory.
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin study enrollment completed; Topline data expected in first half of 2025Clinical progress represents important steps towa.
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.